Gilead buys Tubulis

Gilead is paying $3.15 billion in cash, with another $1.85 billion tied to milestones, to buy a German cancer biotech that most people outside drug development had never heard of a week ago. The agreement was announced on April 7, 2026, and values Tubulis at up to $5 billion. (tubulis.com, reuters.com) Tubulis works on antibody-drug conjugates, which are cancer drugs built like guided packages: an antibody finds a tumor marker, a chemical linker holds the package together in the bloodstream, and a toxic payload is released after the drug reaches the cancer cell. Big drugmakers want these because the whole trick is killing more tumor cells while hitting fewer healthy ones. (tubulis.com, genengnews.com) That linker is the part investors keep paying for. If it breaks too early, the toxic cargo leaks into the body; if it holds until the antibody is inside the tumor cell, the same payload can look much smarter. (tubulis.com, biopharminternational.com) Tubulis built its pitch around two platform technologies called Tubutecan and Alco5, both aimed at making those packages more stable and more precise. The company says its chemistry is designed to widen the “therapeutic window,” meaning a doctor can push dose high enough to hit the tumor before side effects hit the patient. (tubulis.com, pharmexec.com) Gilead is not buying a science project with no human data. Tubulis already has two clinical-stage drug candidates: TUB-040, which targets a protein called NaPi2b, and TUB-030, which targets a protein called 5T4. (tubulis.com, tubulis.com) TUB-040 is already in Phase 1b and Phase 2 testing in platinum-resistant ovarian cancer and non-small cell lung cancer. Tubulis also said in June 2024 that the United States Food and Drug Administration gave TUB-040 Fast Track designation in platinum-resistant ovarian cancer. (pharmexec.com, tubulis.com) This deal did not come out of nowhere. Gilead and Tubulis had already signed an exclusive option and license agreement in December 2024 to develop an antibody-drug conjugate candidate for selected solid tumors, so Gilead had a front-row seat before deciding to buy the whole company. (tubulis.com, tubulis.com) The timing also fits Gilead’s bigger oncology rebuild. Reuters described the Tubulis purchase as the latest step in an acquisition push, and Gilead said the Tubulis team and platform will strengthen its cancer pipeline in areas with high unmet need. (reuters.com, tubulis.com) For Munich, the deal keeps the lab map visible instead of erasing it. Trade coverage says Tubulis is expected to become Gilead’s dedicated antibody-drug conjugate hub in Munich after closing, which is the kind of sentence employees read as both opportunity and reorganization. (pharmexec.com, tubulis.com) The price tells you how hot this corner of cancer drugmaking has become. Tubulis raised €128 million in March 2024 and then €308 million in a Series C round in late 2025, but less than two years later Gilead decided the faster move was to own the platform, the pipeline, and the people outright. (tubulis.com, tubulis.com)